salvage treatment options following car-t failure in dlbcl
Published 7 months ago • 322 plays • Length 2:04Download video MP4
Download video MP3
Similar videos
-
7:35
survey on the evaluation and management of dlbcl following suboptimal response to car-t therapy
-
2:51
novel agents vs. standard chemotherapy for first-line salvage treatment following car-t in lbcl
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
2:06
can car-t cells replace asct in dlbcl?
-
0:32
enhancing outcomes of patients with dlbcl treated with car t-cell therapy
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
19:56
ξυπναμε μαζι ξεκιναμε μαζι γ μεροσ γ. χατζαριδησ & ε. γαβριηλακη 21-11-2019
-
3:08
dynamic cell salvage with the autolog iq™ autotransfusion system
-
1:01:36
deciphering car-t cells: exploring functional mechanisms to drive next generation immunotherapy
-
3:03
the impact of salvage and bridging therapy on car t-cell therapy outcomes in b-all: an itt analysis
-
1:45
comparing salvage transplantion to car t-cell therapy for treating relapsed multiple myeloma
-
1:02
the use of car-t cell products in a real-world setting
-
2:36
managing car-t therapy-related aes & treatment options for patients who progress after car-t therapy
-
1:51
regulatory and commercialization challenges with car t-cell therapy
-
1:42
challenges associated with car-t cell production
-
3:52
updates on the use of car-t therapy for the treatment of dlbcl in the second-line setting
-
3:15
key updates in car-t therapy from eha 2022
-
1:41
the challenges with implementing car-t into the aml treatment landscape
-
2:11
improving treatment outcomes of car t-cell therapy
-
4:24
risks and indications for consolidation allohsct after car t-cell therapy in all